We show the importance of hypoxia in activating enzymes that control proper collagen maturation in eye melanoma. Disrupting this process with an inhibitor of the HIF-1/p300 transcription complex leads to disordered collagen structure and reduces tumor growth in the eye and liver in mice xenografts.

In this study, we showed that combining the second-generation FLT3 inhibitor gilteritinib with the dual PI3K/HDAC inhibitor CUDC-907 synergistically improved anti-leukemic activity against FLT3-ITD acute myeloid leukemia (AML) – and that each agent reciprocally overcame resistance to the other drug.

Breast cancer in women is the most commonly diagnosed cancer worldwide with over 2 million new cases and nearly 700 000 deaths from breast cancer in 2020 (1). Our paper explores if we can be smarter about reducing mortality by targeting screening resources to women who are most likely to benefit.

In a proof-of-principle study published in Blood Cancer Journal, we showed that human CAR T cells can be generated within the host upon injecting an Adeno-associated virus (AAV) vector carrying the CAR gene, which we call AAV delivering CAR gene therapy (ACG).

This work shows how mitochondria chaperone GRP75 regulates the stability of SIX1, a transcription factor for embryonic development and cancer progression. Our findings provide important insights into the protein degradation mechanism as well as a novel avenue for prostate cancer therapy.

Besides eradicating tumour cells with deficiencies for homologous recombination, PARP inhibitors can induce the activation of CAFs within the TME via NF-κB/CCL5 pathway. CCL5 blockade blunts the reprogramming of CAFs conditioned by PARP inhibitors and potentiates PARP inhibitors.